HURA Fundamental Analysis - TUHURA BIOSCIENCES INC

Fundamental Rating

Taking everything into account, HURA scores 1 out of 10 in our fundamental rating. HURA was compared to 528 industry peers in the Biotechnology industry. HURA may be in some trouble as it scores bad on both profitability and health. HURA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

HURA had negative earnings in the past year.
In the past year HURA has reported a negative cash flow from operations.
In the past 5 years HURA always reported negative net income.
HURA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

HURA's Return On Assets of -170.33% is on the low side compared to the rest of the industry. HURA is outperformed by 86.36% of its industry peers.
HURA has a Return On Equity of -260.88%. This is in the lower half of the industry: HURA underperforms 71.40% of its industry peers.

		Industry Rank	Sector Rank
ROA	-170.33%
ROE	-260.88%
ROIC	N/A

ROA(3y)-224%

ROA(5y)-257.81%

ROE(3y)-832.26%

ROE(5y)-1280.11%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HURA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

HURA has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, HURA has more shares outstanding
HURA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

HURA has an Altman-Z score of -9.98. This is a bad value and indicates that HURA is not financially healthy and even has some risk of bankruptcy.
HURA's Altman-Z score of -9.98 is on the low side compared to the rest of the industry. HURA is outperformed by 72.35% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that HURA is not too dependend on debt financing.
HURA's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. HURA outperforms 43.18% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Altman-Z	-9.98

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 0.40 indicates that HURA may have some problems paying its short term obligations.
HURA has a Current ratio of 0.40. This is amonst the worse of the industry: HURA underperforms 91.29% of its industry peers.
HURA has a Quick Ratio of 0.40. This is a bad value and indicates that HURA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.40, HURA is not doing good in the industry: 90.72% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.4
Quick Ratio	0.4

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 65.62% over the past year.

EPS 1Y (TTM)65.62%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%89.78%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, HURA will show a very strong growth in Earnings Per Share. The EPS will grow by 32.17% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-35.87%

EPS Next 2Y-13.73%

EPS Next 3Y-12.79%

EPS Next 5Y32.17%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

HURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HURA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

HURA's earnings are expected to decrease with -12.79% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-13.73%

EPS Next 3Y-12.79%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

HURA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

TUHURA BIOSCIENCES INC

NASDAQ:HURA (1/14/2026, 8:00:02 PM)

Premarket: 0.72 -0.04 (-4.86%)

0.7568

+0.03 (+4.03%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-14 2025-11-14/bmo

Earnings (Next)N/A N/A

Inst Owners10.19%

Inst Owner Change-0.1%

Ins Owners28.63%

Ins Owner ChangeN/A

Market Cap38.79M

Revenue(TTM)N/A

Net Income(TTM)-43.77M

Analysts82.22

Price Target9.75 (1188.32%)

Short Float %9.32%

Short Ratio8.41

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly Dividend0

Dividend Growth(5Y)-52.55%

DP-0.01%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-23.75%

Min EPS beat(2)-62.53%

Max EPS beat(2)15.03%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-15.47%

EPS NQ rev (1m)3.57%

EPS NQ rev (3m)5.26%

EPS NY rev (1m)0.79%

EPS NY rev (3m)4.58%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	2.31
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-1.6

EYN/A

EPS(NY)-0.61

Fwd EYN/A

FCF(TTM)-0.68

FCFYN/A

OCF(TTM)-0.68

OCFYN/A

SpS0

BVpS0.33

TBVpS-0.1

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-170.33%
ROE	-260.88%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-224%

ROA(5y)-257.81%

ROE(3y)-832.26%

ROE(5y)-1280.11%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	58.02%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.4
Quick Ratio	0.4
Altman-Z	-9.98

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)139.9%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)65.62%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%89.78%

EPS Next Y-35.87%

EPS Next 2Y-13.73%

EPS Next 3Y-12.79%

EPS Next 5Y32.17%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-407.44%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-906.28%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-903.22%

OCF growth 3YN/A

OCF growth 5YN/A

TUHURA BIOSCIENCES INC / HURA FAQ

What is the fundamental rating for HURA stock?

ChartMill assigns a fundamental rating of 1 / 10 to HURA.

What is the valuation status for HURA stock?

ChartMill assigns a valuation rating of 0 / 10 to TUHURA BIOSCIENCES INC (HURA). This can be considered as Overvalued.

Can you provide the profitability details for TUHURA BIOSCIENCES INC?

TUHURA BIOSCIENCES INC (HURA) has a profitability rating of 0 / 10.

How sustainable is the dividend of TUHURA BIOSCIENCES INC (HURA) stock?

The dividend rating of TUHURA BIOSCIENCES INC (HURA) is 0 / 10 and the dividend payout ratio is -0.01%.

TUHURA BIOSCIENCES INC (HURA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

TUHURA BIOSCIENCES INC / HURA FAQ

What is the fundamental rating for HURA stock?

What is the valuation status for HURA stock?

Can you provide the profitability details for TUHURA BIOSCIENCES INC?

How sustainable is the dividend of TUHURA BIOSCIENCES INC (HURA) stock?